1354491-91-0

Upstream product

• 867-13-0 diethoxyphosphoryl-acetic acid ethyl ester 
• 6186-22-7 4-bromophenyl acetone 

Downstream Products

• 1447071-15-9 (2S)-ethyl 2-tert-butoxy-2-(1-(4-chlorophenyl)-7-(3-(4-fluorophenyl)-3-hydroxybut-1-ynyl)-3-methylnaphthalen-2-yl)acetate 
• 1354491-73-8 ethyl 2-(7-bromo-1-(4-chlorophenyl)-3-methylnaphthalen-2-yl)-2-tert-butoxyacetate 
• 1354491-72-7 ethyl 2-(7-bromo-1-(4-chlorophenyl)-3-methylnaphthalen-2-yl)-2-hydroxyacetate 
• 1354491-70-5 ethyl 2-(7-bromo-1-(4-chlorophenyl)-3-methylnaphthalen-2-yl)-2-oxoacetate 
• 1354491-71-6 ethyl 2-(1,7-bis(4-chlorophenyl)-3-methylnaphthalen-2-yl)-2-oxoacetate 
• 1447071-17-1 (S)-((1R,2S,5R)-2-isopropyl-5-methylcyclohexyl)-2-(7-bromo-1-hydroxy-3-methylnaphthalen-2-yl)-2-tert-butoxyacetate 
• 1447068-79-2 (2S)-2-tert-butoxy-2-(1-(4-chlorophenyl)-7-(3-(4-fluorophenyl)-3-hydroxybut-1-ynyl)-3-methylnaphthalen-2-yl)acetic acid 
• 13615-40-2 3-methylnaphthalen-1-ol 

Relevant academic research and scientific papers

The design of a spiro-pyrrolidine organocatalyst and its application to catalytic asymmetric Michael addition for the construction of all-carbon quaternary centers

A novel chiral spiro-pyrrolidine silyl ether organocatalyst has been designed. Its catalytic asymmetric effect is demonstrated by the Michael addition reaction, which affords the desired products with an all-carbon quaternary center in up to 99% ee and 87

NAPTHALENE ACETIC ACID DERIVATIVES AGAINST HIV INFECTION

The invention provides compounds and salts thereof as d herein. The invention also provides pharmaceutical compositions comprising a compound disclosed herein, processes for preparing compounds disclosed herein, intermediates useful for preparing compound

NAPHT- 2 -YLACETIC ACID DERIVATIVES TO TREAT AIDS

The invention provides compounds of formula (I): or a salt thereof as described herein. The invention also provides pharmaceutical compositions comprising a compound of formula I, processes for preparing compounds of formula (I), intermediates useful for preparing compounds of formula I and therapeutic methods for treating the proliferation of the HIV virus, treating AIDS or delaying the onset of AIDS or ARC symptoms in a mammal using compounds of formula (I).